Liquidia Technologies Inc. (LQDA) and Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) Comparing side by side

Both Liquidia Technologies Inc. (NASDAQ:LQDA) and Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Liquidia Technologies Inc. 1.78M 90.44 39.39M -3.40 0.00
Kiniksa Pharmaceuticals Ltd. N/A 0.00 153.07M -3.03 0.00

Table 1 highlights Liquidia Technologies Inc. and Kiniksa Pharmaceuticals Ltd.’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 shows the return on assets, return on equity and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Liquidia Technologies Inc. -2,212.92% 0% 0%
Kiniksa Pharmaceuticals Ltd. 0.00% -49.1% -44.4%

Liquidity

Liquidia Technologies Inc. has a Current Ratio of 5.6 and a Quick Ratio of 5.6. Competitively, Kiniksa Pharmaceuticals Ltd.’s Current Ratio is 9.1 and has 9.1 Quick Ratio. Kiniksa Pharmaceuticals Ltd.’s better ability to pay short and long-term obligations than Liquidia Technologies Inc.

Analyst Ratings

Liquidia Technologies Inc. and Kiniksa Pharmaceuticals Ltd. Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Liquidia Technologies Inc. 0 0 0 0.00
Kiniksa Pharmaceuticals Ltd. 0 0 1 3.00

Kiniksa Pharmaceuticals Ltd. on the other hand boasts of a $26 average price target and a 90.06% potential upside.

Insider & Institutional Ownership

Roughly 44.4% of Liquidia Technologies Inc. shares are owned by institutional investors while 73.1% of Kiniksa Pharmaceuticals Ltd. are owned by institutional investors. About 1.1% of Liquidia Technologies Inc.’s share are owned by insiders. Competitively, 8.38% are Kiniksa Pharmaceuticals Ltd.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Liquidia Technologies Inc. -0.1% -0.2% -31.03% -48.27% 0% -54.43%
Kiniksa Pharmaceuticals Ltd. 0.87% -11.22% -13.95% -24.22% 0% -46.21%

For the past year Liquidia Technologies Inc. was more bearish than Kiniksa Pharmaceuticals Ltd.

Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of human therapeutics. Its lead product candidate, LIQ861, an inhaled dry powder formulation of treprostinil that is in Phase III clinical trials used for the treatment of pulmonary arterial hypertension. The company is also developing LIQ865, which completed Phase Ib clinical trials for the treatment of local post-operative pain. It has strategic collaboration agreements with GlaxoSmithKline plc and Aerie Pharmaecuticals, Inc. Liquidia Technologies, Inc. was incorporated in 2004 and is headquartered in Morrisville, North Carolina.

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.